Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec;6(4):171-7.
doi: 10.1007/s10048-005-0005-1. Epub 2005 Sep 17.

Lrrk2 pathogenic substitutions in Parkinson's disease

Affiliations

Lrrk2 pathogenic substitutions in Parkinson's disease

Ignacio F Mata et al. Neurogenetics. 2005 Dec.

Abstract

Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein. To identify novel LRRK2 mutations, we have sequenced 100 affected probands with family history of parkinsonism. Semiquantitative analysis was also performed in all probands to identify LRRK2 genomic multiplication or deletion. In these kindreds, referred from movement disorder clinics in many parts of Europe, Asia, and North America, parkinsonism segregates as an autosomal dominant trait. All 51 exons of the LRRK2 gene were analyzed and the frequency of all novel sequence variants was assessed within controls. The segregation of mutations with disease has been examined in larger, multiplex families. Our study identified 26 coding variants, including 15 nonsynonymous amino acid substitutions of which three affect the same codon (R1441C, R1441G, and R1441H). Seven of these coding changes seem to be pathogenic, as they segregate with disease and were not identified within controls. No multiplications or deletions were identified.

PubMed Disclaimer

Similar articles

  • Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
    Hatano T, Funayama M, Kubo SI, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto KI, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N. Hatano T, et al. Neurobiol Aging. 2014 Nov;35(11):2656.e17-2656.e23. doi: 10.1016/j.neurobiolaging.2014.05.025. Epub 2014 Jun 2. Neurobiol Aging. 2014. PMID: 24973808 Free PMC article.
  • LRRK2 R1441G in Spanish patients with Parkinson's disease.
    Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V. Mata IF, et al. Neurosci Lett. 2005 Jul 15;382(3):309-11. doi: 10.1016/j.neulet.2005.03.033. Epub 2005 Apr 13. Neurosci Lett. 2005. PMID: 15925109
  • Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.
    Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohé CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V; Italian Parkinson's Genetics Network. Di Fonzo A, et al. Eur J Hum Genet. 2006 Mar;14(3):322-31. doi: 10.1038/sj.ejhg.5201539. Eur J Hum Genet. 2006. PMID: 16333314
  • Clinical features of LRRK2 parkinsonism.
    Haugarvoll K, Wszolek ZK. Haugarvoll K, et al. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
  • Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.
    Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK. Whaley NR, et al. J Neural Transm Suppl. 2006;(70):221-9. doi: 10.1007/978-3-211-45295-0_34. J Neural Transm Suppl. 2006. PMID: 17017533 Review.

Cited by

References

    1. Adv Neurol. 2003;91:133-42 - PubMed
    1. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
    1. Ann N Y Acad Sci. 2003 Jun;991:1-14 - PubMed
    1. Lancet. 2005 Jan 29-Feb 4;365(9457):415-6 - PubMed
    1. Ann Neurol. 2005 Mar;57(3):365-72 - PubMed

Publication types

Substances

LinkOut - more resources